PEER-REVIEWED · ANNALS OF ONCOLOGY · 2025

→

LUCC Lung: Europe's Largest Structured Lung Cancer Cohort

A curated, longitudinal dataset of 30,000 patients across 25 centers, covering all histologies, biomarker profiles, and treatment lines extracted by clinical AI from routine care documents, updated daily.

REQUEST A FEASIBILITY ASSESSMENT

30,000

Patients inclus

Centres

Études en vie réelle

Dec 2023

Date de lancement

A living data layer for lung cancer research.
Evidence takes years to produce. Practice changes in months. LUCC Lung updates a research-grade dataset every single day, so new therapies reach patients sooner.

data

Continuously updated

Longitudinal data points are updated daily. This is not a point-in-time extract.

TRACEABILITY

Source-linked

Every variable is traced back to its original clinical document.

PRIVACY

GDPR-native

Privacy by design. Pseudonymization at the point of care.

INFRASTRUCTURE

ISO 27001 · HDS

Certified secure hosting for health data.

METHODOLOGY

Listed by HAS

Referenced by France's National Authority for Health as a real-world data source for health product assessments.

Guided by leading thoracic oncologists

Every study on LUCC Lung is designed and reviewed by an independent scientific committee of 9 experts across top cancer and respiratory medicine centers.

SEC Chair - LUCC Lung

Pr. Benjamin Besse

Head of Clinical Research, Institut Gustave Roussy · Professor of Oncology, Paris-Saclay University

H-INDEX : 111 · 69,000+ CITATIONS · GOOGLE SCHOLAR

Dr Hubert Curcio

Medical oncologist,
Centre François Baclesse

Dr Elvire Pons-Tostivint

Thoracic oncologist,
Nantes University Hospital

Pr. Emmanuel Bergot

Early-phase oncology
Bergonié Cancer Center, Bordeaux

Pr Jaafar Bennouna

Head of Medical Oncology,
Foch Hospital

Dr Virginie Levrat

Pulmonologist,
La Rochelle Hospital

Dr Nicolas Cloarec

Head of Thoracic Oncology,
Avignon Hospital

Dr. Nicolas Rezvoy

Radiation oncologist
La Louvière Private Hospital

Laure Guéroult-Accolas

Founder & Managing Director,
Patients en réseau (patient advocacy)

Franck Le Ouay

Co-founder & CEO,
Lifen

New member TBD

This is some text inside of a div block.

LUCC Lung at a glance

Longitudinal clinical data structured by clinical AI from routine care documents, updated daily.

Cohort growth

Cumulative patients, centers and countries

H2 '23

H1 '24

H2 '24

12K

H1 '25

17K

H2 '25

25K

H1 '26

TARGET

40K

2027-28

Centers

Countries

🇫🇷

🇧🇪

🇪🇸 🇩🇪

H2 '23

X centers · 🇫🇷

H1 '24

X centers

H2 '24

X centers

H1 '25

12K

X centers

H2 '25

17K

X centers

H1 '26

25K

25 centers · + 🇧🇪

2027-28

40K

TARGET · 35 centers · + 🇪🇸 🇩🇪

Figures through H1 2026 are actuals. 2027-28 reflects the network expansion roadmap: Germany and Spain.

The largest structured lung cancer hospital network in France

Carte de France des 28 centres du réseau LUCC : 12 centres académiques (CHU et CLCC) et 16 centres communautaires, répartis sur tout le territoire

Centers

Type

Sites

Academic Medical Centers

University hospitals (CHU) & cancer centers (CLCC)

Community Centers

Community, private & non-profit hospitals

Total

Community hospital

Cancer center (CLCC)

Non-profit hospital

University hospital (CHU)

Private hospital

Actionable biomarkers

Patients with alteration detected

1,914

KRAS

1,396

EGFR

410

ALK

308

BRAF

266

MET

210

PIK3CA

HER2

ROS1

RET

NTRK

PD-L1

Treatment modalities

This is a subset of treatments given for illustrative purposes only.

PD-1 / PD-L1 inhibitors

Pembrolizumab · Durvalumab · Nivolumab · Atezolizumab

5,217

EGFR TKIs

Osimertinib · Erlotinib · Gefitinib · Lazertinib

1,092

ALK TKIs

Crizotinib · Alectinib · Lorlatinib · Brigatinib

844

Anti-VEGF

Bevacizumab

628

KRAS G12C inhibitors

Sotorasib · Adagrasib

193

CTLA-4

Ipilimumab

121

RET inhibitors

Selpercatinib · Pralsetinib

BRAF / MEK

Dabrafenib · Trametinib

25,696 treatment records across the cohort.

Request detailed breakdown for your molecule →

Data dictionary

Clinical variables curated from unstructured medical documents. Additional variables available on demand for study-specific needs.

Studies already running on LUCC Lung

Research questions answered with LUCC Lung Research cohort.

featured study

EGFR-Predict

ANALYSIS ONGOING

Can a predictive score help personalise the choice between osimertinib alone and osimertinib plus chemotherapy in EGFR-mutated NSCLC?

292

patients

Centers

Dr Nadia Guezour

Principal investigator, Groupe Hospitalier Paris Saint-Joseph

INVESTIGATOR-INITIATED STUDIES

All approved by the Scientific Evaluation Committee.

Study

Research question & principal investigator

PDL1-HIGH

Descriptive and survival analysis of PD-L1 ≥50% NSCLC treated with first-line chemo-immunotherapy.

Dr Nuccio, Gustave Roussy

ICARE

Value of targeted radiotherapy on brain metastases in asymptomatic patients without actionable molecular alterations.

Dr Helissey, Groupe Hospitalier Paris Saint-Joseph

YOUNG40

Tumor characteristics and care pathway in patients diagnosed under 40.

Dr Colamartini / Dr Aldea, Gustave Roussy

Apex

Care pathway of patients with Pancoast-Tobias syndrome.

Dr Pons-Tostivint, CHU de Nantes

BRAFVISION

Clinical characteristics and treatment outcomes of BRAF V600E NSCLC.

Pr Bennouna, Hôpital Foch

RepliCate

Compare real-world outcomes in LUCC with reference clinical trial populations.

Dr Aldea, Gustave Roussy

INDUSTRY-SPONSORED STUDIES

Sponsor names are disclosed at publication.

Study

Research question

ALK-IA

Real-world outcomes of first-line ALK TKIs in ALK+ NSCLC.

ANALYSIS ONGOING

MONARCH

EGFR patient care pathways with SNDS linkage.

RESULTS IN PREPARATION

RECOG-KRAS

KRAS G12C treatment patterns. European multi-country study.

"Lifen structures complex clinical data from real-world documents with remarkable accuracy. This cohort gives us the scale and granularity we need to answer questions that clinical trials cannot."

Dr. Mihaela Aldea

Thoracic oncologist, Gustave Roussy

Lorem Ipsum is simply dummy of the printing and typesetting industry. Lorem Ipsum has been the industry's.

Author Name

VP of Company

Lorem Ipsum is simply dummy of the printing and typesetting industry. Lorem Ipsum has been the industry's.

Author Name

VP of Company

Lorem Ipsum is simply dummy of the printing and typesetting industry. Lorem Ipsum has been the industry's.

Author Name

VP of Company

Annals of Oncology · December 2025

3.2× fewer errors than manual abstraction

311 patients, 31 clinical variables and 10 centers. Three structuring methods compared head to head.

4.4%

error rate of the method behind LUCC Lung

vs 14.2% for manual abstraction

9,641

data points independently adjudicated

311 patients × 31 clinical variables

31/31

variables where AI outperformed manual abstraction

across all 10 participating centers

Error rate by structuring method

Share of the 9,641 data points incorrectly extracted · lower is better

Manual abstraction

14.2%

AI extraction

7.0%

Hybrid (AI + targeted human review)

4.4%

LUCC Lung is structured with the hybrid method. AI extraction alone already outperformed manual abstraction on all 31 variables and in all 10 centers.

Read the study in Annals of Oncology →